NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Influenza H5N1 prevention
Date of first enrollment
Target sample size
Countries of recruitment
Study type	INTERVENTIONAL
Intervention(s)	Intervention name : KD-295 Dosage And administration of the intervention : Administer 0.25 mL or 0.5 mL of KD-295 by intramuscular injection in the extensor surface of the upper arm twice at an interval of 21 days (±2 days), alternating injection sites between the left and the right arms. Control intervention name : null

Outcome(s)

Primary Outcome	null
Secondary Outcome	null

Key inclusion & exclusion criteria

Age minimum	20
Age maximum	40
Gender	Male
Include criteria	(1) Subjects who are healthy adult males aged between 20 and 40 inclusive at the time of obtaining informed consent. (2) Subjects who are judged as eligible healthy adults for this clinical study by the principal investigator or subinvestigator based on the screening results. (3) Subjects who are able to give written informed consent, follow compliance rules while participating in this clinical study, receive medical examination and testing described in this protocol and report symptoms and other signs.
Exclude criteria